FREESTYLE LITE
Device
Abbott Laboratories
Total Payments
$349,195
Transactions
166
Doctors
8
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $88.19 | 1 | 1 |
| 2023 | $56,064 | 4 | 2 |
| 2022 | $293,043 | 161 | 5 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $346,390 | 156 | 99.2% |
| Compensation for serving as faculty or as a speaker for a medical education program | $1,700 | 1 | 0.5% |
| Consulting Fee | $850.00 | 1 | 0.2% |
| Food and Beverage | $228.52 | 7 | 0.1% |
| Travel and Lodging | $26.25 | 1 | 0.0% |
Payments by Type
Research
$346,390
156 transactions
General
$2,805
10 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Multi-Analyte Studies | Abbott Laboratories | $265,908 | 0 |
| The Relation between Mean Glucose and HbA1c in Ugandan Youth with T1D: An Observational Study | Abbott Laboratories | $30,990 | 0 |
| Effect of Glucose Fluctuations on Atrial Fibrillation Burden among Patients with Diabetes Mellitus and Paroxysmal Atrial Fibrillation or Recent Atrial Fibrillation Ablation | Abbott Laboratories | $25,000 | 0 |
| Diabetes in African Youth: Lowering Glucose and HbA1c Trial | Abbott Laboratories | $14,157 | 0 |
| Individualized Structured Meal Plans to Improve Glycemic Control in Adolescents with Type 1 Diabetes (T1D) | Abbott Laboratories | $2,158 | 0 |
| Efficacy of Flash Continuous Glucose Monitoring During the Transition from Inpatient to Outpatient Care in Patients with Type 2 Diabetes after Coronary Artery Bypass Graft (CABG) Surgery | Abbott Laboratories | $1,838 | 0 |
| Diabetes Discharge Transition Continuous Glucose Monitor Study (CGM Study) | Abbott Laboratories | $1,561 | 0 |
| Surgical or Medical Therapy for Pediatric Type 2 Diabetes (ST2OMP) | Abbott Laboratories | $1,485 | 0 |
| Effect of Empagliflozin glucose variability (GV) and myocardial perfusion in type II diabetes (T2DM) | Abbott Laboratories | $1,096 | 0 |
| Does GEM significantly enhance the benefit of CGM in the management of adults with pre-diabetes? | Abbott Laboratories | $1,032 | 0 |
| Impact of Flash Glucose Monitoring on Behavior Modification, Quality of Life, and Treatment Satisfaction in Non-Insulin Treated Patients with Type 2 Diabetes | Abbott Laboratories | $989.71 | 0 |
| Identifying High Risk for Cystic Fibrosis Related Diabetes Through the use of Continuous Glucose Monitoring and Fructosamine | Abbott Laboratories | $174.84 | 0 |
Top Doctors Receiving Payments for FREESTYLE LITE
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Columbus, OH | $346,390 | 156 |
| , D.O | Obesity Medicine | Bend, OR | $2,576 | 3 |
| , MD | Endocrinology, Diabetes & Metabolism | Newport Beach, CA | $88.19 | 1 |
| George Grunberger | — | Bloomfield Hills, MI | $62.51 | 1 |
| , M.D., P.A | Pediatrics | Richardson, TX | $18.32 | 1 |
| , MD | General Practice | Richardson, TX | $17.28 | 1 |
| , M.D | Specialist | Dallas, TX | $15.51 | 1 |
| , PA | Medical | Mckinney, TX | $15.51 | 1 |
| , MD | Endocrinology, Diabetes & Metabolism | Saint Louis, MO | $11.20 | 1 |
Ad
Manufacturing Companies
- Abbott Laboratories $349,195
Product Information
- Type Device
- Total Payments $349,195
- Total Doctors 8
- Transactions 166
About FREESTYLE LITE
FREESTYLE LITE is a device associated with $349,195 in payments to 8 healthcare providers, recorded across 166 transactions in the CMS Open Payments database. The primary manufacturer is Abbott Laboratories.
Payment data is available from 2022 to 2024. In 2024, $88.19 was paid across 1 transactions to 1 doctors.
The most common payment nature for FREESTYLE LITE is "Unspecified" ($346,390, 99.2% of total).
FREESTYLE LITE is associated with 12 research studies, including "Multi-Analyte Studies" ($265,908).